Drug news
Revance Therapeutics to initiate Phase III trial for RT 001 for treatment of Facial Wrinkles
Revance Therapeutics inc has secured the funding necessary to initiate a Phase III trial for Botulinum Toxin Type A Topical Gel for the treatment of facial wrinkles (crows feet) that is intended to compete with injected therapies such as Botox.
RT 001 is also currently in Phase II trials for the topical treatment of hyperhidrosis (excessive sweating), and chronic migraine headache.